TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07165132: Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Sponsor: RayzeBio, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 104 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,130,976

Unlock Full NCT07165132 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07165132 Rescue Dossier →